Clinical importance of serum hepatitis B surface antigen levels in chronic hepatitis B

Journal of Viral Hepatitis

Volumn 18, Issue 10, 2011, Pages

  Togo, S ^a   Arai, M ^a   Tawada, A ^a   Chiba, T ^a   Kanda, T ^a   Fujiwara, K ^a   Imazeki, F ^a   Yokosuka, O ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

chronic hepatitis B; HBeAg seroconversion; HBs antigen quantification

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEROCONVERSION; THROMBOCYTE COUNT;

ADULT; BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROGNOSIS; SERUM; TREATMENT OUTCOME;

EID: 80052833915     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01486.x     Document Type: Article

References (35)

1. Lok AS, McMahon BJ,. Chronic hepatitis B. AASLD practice guidelines. Hepatology 2007; 45: 507-539.
2. Ganem D, Prince AM,. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129. (Pubitemid 38298992)
3. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS,. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-1075. (Pubitemid 46646501)
4. Liaw YF,. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005; 25: 40-47.
5. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB,. Seroconversion from hepatitis e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94: 744-748. (Pubitemid 11123366)
6. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6: 167-172. (Pubitemid 16144862)
7. Yuen MF, Yuan HJ, Wong DK, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54: 1610-1614. (Pubitemid 41531781)
8. Hui CK, Leung N, Shek TW, et al. Sustained disease remission reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 2007; 46: 690-698.
9. Ito K, Arai M, Imazeki F, et al. Risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Scand J Gastroenterol 2010; 45: 243-249.
10. Bekku D, Arai M, Imazeki F, et al. Long-term follow-up in patients with hepatitis B e antigen negative chronic hepatitis B. J Gastroenterol Hepatol 2011; 26: 122-128.
11. Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ,. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32: 1323-1331.
12. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ,. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52: 1232-1241.
13. Chu CM, Liaw YF,. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007; 133: 1458-1465.
14. Blumberg BS, Alter HJ, Visnich S,. A "new" antigen in leukemia sera. JAMA 1965; 191: 541-546.
15. Nguyen DH, Hu J,. Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J Virol 2008; 82: 6852-6861. (Pubitemid 351977706)
16. Op den Brouw ML, Binda RS, Geijtenbeek TB, Janssen HL, Woltman AM,. The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells. Virology 2009; 393: 84-90.
17. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-1944.
18. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004; 115: 217-222. (Pubitemid 37506037)
19. Kohmoto M, Enomoto M, Tamori A, et al. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 2005; 75: 235-239. (Pubitemid 40053734)
20. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-513.
21. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus. J Hepatol 2010; 52: 514-522.
22. Wiegand J, Wedemeyer H, Finger A, et al. A decline in hepatitis B virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels. Antivir Ther 2008; 13: 547-554. (Pubitemid 352016717)
23. Yuen MF, Wong DK, Fung J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-1199.
24. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295-301. (Pubitemid 20237094)
25. Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-2097.
26. Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-1325.
27. Chien RN, Liaw YF, Akins M,. Pretherapy alanine transaminase level as a determinant for hepatitis B e seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian hepatitis lamivudine trial group. Hepatology 1999; 30: 770-774.
28. Yuen MF, Fung SK, Tanaka Y, et al. Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C. J Clin Microbiol 2004; 42: 5036-5040. (Pubitemid 39506207)
29. Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428-434. (Pubitemid 351280710)
30. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-194. (Pubitemid 34700777)
31. Liu CJ, Chen PJ, Lai MY, et al. Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B. Liver Int 2006; 26: 949-955.
32. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-461.
33. Zoulim F,. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302-308. (Pubitemid 40254242)
34. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758. (Pubitemid 38736340)
35. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-1468. (Pubitemid 350181604)